NUS

5 low price-to-sales stocks passed a value screen that combines valuation, debt and quality metrics to highlight potential upside opportunities.

Nu Skin Enterprises (NUS) faces low profitability and macro-driven sales headwinds, with limited recession resistance and weak operating cash flow. The India market expansion is a key strategic focus, but execution risks are high and infrastructure investments will elevate fixed costs. NUS's working capital intensity pose cash flow risks even in growth, despite low net debt and recent refinancing extending maturities to 2031.

EL, HELE, NUS, KVUE and IPAR stand out as beauty and cosmetics stocks backed by growth strategies for 2H 2026.

Nu Skin (NUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

EL, ELF, HELE and NUS are benefiting from growing skincare demand, product innovation and expanding digital channels.

CAL, GIII, NUS, APLE and EVER screen as low price-to-sales value stocks with upside potential, backed by valuation and debt filters.

The June GVAS portfolio highlights 13 'safer,' fair-priced large-cap value stocks with strong dividend yields and positive free cash flow margins. Top ten GVAS stocks are forecasted to deliver average net gains of 39.68% by June 2027, with yields ranging from 7.9% to 16.46%. Energy and financial sectors dominate the highest-yielding, lowest-priced GVAS, with Okeanis Eco Tankers and IRSA Inversiones offering standout upside potential.

Price-to-sales screens can uncover discounted growth when earnings are thin, pairing low P/S with balance-sheet and value checks for upside.

Low price-to-sales stocks like SCVL, NUS, APLE, COP and FAF screen as undervalued, with the setup hinging on debt levels, strong cash flow and business momentum.

EL, NUS and COTY tap AI, wellness and innovation trends as beauty demand evolves across skincare, cosmetics and fragrance categories.